![1]()
News
How to reboot elective CV procedures after COVID-19 lockdown
June 26, 2020
Top cardiology societies provide strategies and considerations for ramping up elective CV imaging, electrophysiology, and remote arrhythmia monitoring as restrictions ease.
![1]()
News
COVID-19: ‘dramatic’ surge in out-of-hospital cardiac arrests in NYC
June 26, 2020
At the height of the COVID-19 pandemic in New York City, first responders faced nearly triple the number of calls for cardiac arrest compared with the same period a year earlier.
![1]()
News
Dapagliflozin benefits low-EF heart failure regardless of diuretic dose: DAPA-HF
June 26, 2020
The trial that turned an SGLT2 inhibitor into a heart failure drug also has clues to mechanisms behind the observed benefits. Contrary to early speculation, diuresis may be off the list.
![1]()
News
VA readmissions program not linked to increased death
June 26, 2020
Unlike CMS’s hospital readmissions program, the VA’s program had no financial penalties. A new analysis shows heart failure readmissions are down and mortality unchanged in the VA setting.
![1]()
News
ED visits for life-threatening conditions declined early in COVID-19 pandemic
June 23, 2020
Visits for MI, stroke, and hypoglycemic crisis dropped 10%-23% over the first 10 weeks.
![1]()
News
Cost of preventable adult hospital stays topped $33 billion in 2017
June 23, 2020
Heart failure, diabetes, and COPD were the most expensive preventable conditions.
News
CVD risk continues to fall down to systolic BP of 90 mm HG
June 19, 2020
“From an individual level we can now say that in healthy individuals, a systolic pressure in the 90s is not too low. It is a positive thing.”
![1]()
Opinion
Preventing arrhythmias and QTc prolongation in COVID-19 patients on psychotropics
June 18, 2020
Psychotropics associated with QTc interval prolongation should be discontinued (or substituted with a low-risk agent) if a patient presents with suspected COVID-19.
![1]()
News
DAPA-HF: Dapagliflozin slows T2D onset in heart failure patients
June 16, 2020
In the landmark DAPA-HF trial that enrolled HFrEF patients without diabetes, treatment with dapagliflozin cut incident type 2 diabetes by a relative 32%.
News
Mortality differs by LVEF between women and men
June 12, 2020
An Australian big-data study shows that a left-ventricular ejection fraction above 70% in women spells trouble
